Is using macropod-derived products a viable treatment option for a patient with asthma?

Macropods for Asthma

There is no evidence supporting the use of macropod-derived products for asthma treatment, and this is not a recognized therapeutic option in any asthma management guidelines.

Clarification of Terminology

The term "macropods" refers to marsupials (kangaroos, wallabies), not medications. Based on the context of your question and the available evidence, you are likely asking about macrolides (antibiotics such as azithromycin, clarithromycin, erythromycin), not macropods. I will address macrolide therapy for asthma below.

---

Macrolides in Asthma Management

Primary Recommendation

Macrolides should only be considered in a highly specific subset of adult asthma patients who have failed optimized standard therapy, and even then, the benefits are modest. 1

Who Might Benefit

Macrolide therapy could be considered for adults aged 50-70 years with all of the following criteria: 1

• Ongoing asthma symptoms despite >80% adherence to high-dose inhaled corticosteroids (>800 μg/day)
• Currently using a long-acting beta-agonist
• At least one exacerbation requiring oral steroids in the past year
• Optimized inhaler technique and confirmed adherence to current therapy

Specific Regimen with Evidence

Azithromycin 500 mg three times weekly for 48 weeks is the regimen with the strongest evidence for reducing exacerbations. 1 This recommendation is based on the AMAZES randomized controlled trial, which represents the highest quality evidence available. 1

What Macrolides Can and Cannot Do

Benefits (all modest in magnitude): 1

• Reduction in exacerbation frequency in the specific population described above
• Small improvements in quality of life (often below the minimal clinically important difference)
• Possible small improvements in lung function and peak expiratory flow rate
• Potential reduction in airway inflammation and bronchial hyperresponsiveness

What macrolides do NOT do: 1

• Should NOT be used to reduce oral steroid dose (this is a strong recommendation against)
• No evidence of impact on mortality
• No evidence of impact on exercise capacity
• No evidence of impact on disease progression

Recent High-Quality Evidence

A 2024 systematic review and meta-analysis found that macrolides did not significantly reduce hospitalizations, severe exacerbations, or rescue inhaler use in adult asthma patients. 2 The improvements in asthma control and quality of life were statistically significant but less than the minimal clinically important difference, meaning the clinical relevance is questionable. 2

Safety Considerations and Mandatory Screening

Before initiating macrolide therapy: 1

• ECG is mandatory to assess QTc interval
  • Contraindicated if QTc >450 ms (men) or >470 ms (women)
• Baseline liver function tests should be obtained
• Screen for non-tuberculous mycobacterial infection (if macrolides are used as monotherapy in NTM, resistance develops)

Common adverse effects: 1

• Gastrointestinal symptoms (nausea, abdominal pain, diarrhea) occur more frequently than placebo
• Development of macrolide-resistant bacteria in sputum (clinical significance unclear)

Duration of Therapy

Treatment should be continued for a minimum of 6-12 months to assess efficacy in reducing exacerbations. 1 Shorter courses have insufficient evidence for benefit. 1

Critical Prerequisites

Before considering macrolides, the following must be completed: 1

1. Optimization of inhaled corticosteroid therapy
2. Confirmation of >80% adherence to current medications
3. Verification of proper inhaler technique
4. Addition of long-acting beta-agonist if not already prescribed
5. Referral to or consultation with a respiratory specialist or specialist asthma service

Standard Asthma Therapy Remains Primary

Inhaled corticosteroids remain the preferred long-term control therapy for asthma in all age groups. 1 Beta-2 agonists are first-line bronchodilators for acute symptoms. 3, 4 Macrolides are not part of standard stepwise asthma management and should only be considered after failure of evidence-based therapies. 1, 5

Key Pitfall to Avoid

Do not use macrolides as a substitute for optimizing standard asthma therapy. 1 The evidence for macrolides is of low quality with small effect sizes, whereas inhaled corticosteroids have robust evidence for efficacy. 1, 4, 5 Macrolides represent an adjunctive option only after standard therapy has been maximized and adherence confirmed. 1